{"title":"[Long COVID-A New Challenge in Medicine: Focus on Pregnancy and Breastfeeding].","authors":"Emilie Han, Mariann Gyöngyösi","doi":"10.1007/s41974-023-00250-5","DOIUrl":"https://doi.org/10.1007/s41974-023-00250-5","url":null,"abstract":"<p><p>Long COVID (coronavirus disease) has been described as a new multi-organ disease, which appears to be more prevalent in women than in men. Pregnant and breastfeeding women are a special subgroup of patients to consider with long COVID, as only scarce data have been collected to date. Menstrual changes are commonly observed during or after COVID-19; some studies also attribute slight changes of cycle length to previous inoculation against the virus. Pregnant women who have a symptomatic infection with severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) are at a higher risk for adverse outcomes and pregnancy-associated complications. Moreover, more and robust data are required to evaluate vertical transmission. COVID vaccines are the most effective tool against the pandemic, as they prevent infection, but also appear to be able to ease long COVID symptoms. Vaccines have been proven safe and effective in both pregnant and breastfeeding women. This article aims to present current data on long COVID in pregnant and breastfeeding women and elucidate risk factors and possible treatment options.</p>","PeriodicalId":40002,"journal":{"name":"Journal fur Gynakologische Endokrinologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9472647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Targeted Therapy in Metastatic Breast Cancer-Which Molecular Tests Are Necessary?]","authors":"Marcus Schmidt","doi":"10.1007/s41974-020-00141-z","DOIUrl":"https://doi.org/10.1007/s41974-020-00141-z","url":null,"abstract":"<p><p>In recent years, targeted therapy for breast cancer has received increasingly more attention. In addition to hormone receptors and human epidermal growth factor 2 (HER2), the immunohistochemical detection of programmed cell death ligand 1 (PD-L1) in advanced triple-negative breast cancer and the detection of mutations in the breast cancer 1 (BRCA1) or BRCA2 gene in the patient's germline and mutations in the phosphatidylinositol 3 kinase (PI3K) pathway are currently relevant when making decisions regarding targeted therapy.</p>","PeriodicalId":40002,"journal":{"name":"Journal fur Gynakologische Endokrinologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s41974-020-00141-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38302780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}